Protagenic Short Long Term Debt vs Accounts Payable Analysis
| PTIX Stock | USD 1.32 0.09 6.38% |
Protagenic Therapeutics financial indicator trend analysis is much more than just breaking down Protagenic Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Protagenic Therapeutics is a good investment. Please check the relationship between Protagenic Therapeutics Short Long Term Debt and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.
Short Long Term Debt vs Accounts Payable
Short Long Term Debt vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Protagenic Therapeutics Short Long Term Debt account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Protagenic Therapeutics' Short Long Term Debt and Accounts Payable is -0.22. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Protagenic Therapeutics, assuming nothing else is changed. The correlation between historical values of Protagenic Therapeutics' Short Long Term Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Protagenic Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Long Term Debt i.e., Protagenic Therapeutics' Short Long Term Debt and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.22 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Accounts Payable
An accounting item on the balance sheet that represents Protagenic Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Protagenic Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from Protagenic Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Protagenic Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.Selling General Administrative is likely to drop to about 1.1 M in 2024. Issuance Of Capital Stock is likely to drop to 0.00 in 2024
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 37.0 | 30.0 | 1.6K | 1.7K | Interest Income | 33.2K | 185.8K | 303.2K | 318.4K |
Protagenic Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Protagenic Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protagenic Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 842.3K | 879.2K | 11.1M | 8.0M | 4.3M | 4.1M | |
| Other Current Liab | 1.2M | 513.3K | 520.6K | 105.9K | 655.1K | 622.4K | |
| Total Current Liabilities | 1.2M | 655.2K | 799.5K | 1.1M | 655.3K | 622.5K | |
| Total Stockholder Equity | (634.4K) | (1.1M) | 9.9M | 6.9M | 3.7M | 6.1M | |
| Property Plant And Equipment Net | 611.0 | 296.0 | 0.0 | 1.8K | 123.3K | 117.2K | |
| Net Debt | (519.3K) | 702.7K | (222.7K) | 129.0K | (1.3M) | (1.4M) | |
| Retained Earnings | (15.2M) | (17.7M) | (22.2M) | (25.8M) | (30.8M) | (32.3M) | |
| Cash | 798.6K | 671.1K | 541.2K | 215.2K | 1.3M | 2.0M | |
| Non Current Assets Total | 611.0 | 296.0 | 0.0 | 1.8K | 123.3K | 117.2K | |
| Non Currrent Assets Other | 1.0K | 611.0 | 296.0 | 1.8K | (1.0) | (0.95) | |
| Cash And Short Term Investments | 798.6K | 671.1K | 10.4M | 8.0M | 4.1M | 4.0M | |
| Liabilities And Stockholders Equity | 842.3K | 879.2K | 11.1M | 8.0M | 4.3M | 4.1M | |
| Non Current Liabilities Total | 161.0 | 52.4K | 279.4K | 1.4M | 318.4K | 1.0M | |
| Other Current Assets | 43.4K | 208.2K | 688.7K | 56.9K | 144.0K | 136.8K | |
| Other Stockholder Equity | 14.7M | 16.7M | 32.4M | 33.4M | 34.6M | 42.6M | |
| Total Liab | 1.5M | 2.0M | 1.1M | 1.1M | 655.3K | 622.5K | |
| Total Current Assets | 842.0K | 879.2K | 11.1M | 8.0M | 4.2M | 7.2M | |
| Accumulated Other Comprehensive Income | (172.4K) | (171.6K) | (248.3K) | (676.9K) | (113.5K) | (119.2K) | |
| Accounts Payable | 36.2K | 141.9K | 278.9K | 669.7K | 113.8 | 108.11 | |
| Net Tangible Assets | (210.9K) | (634.4K) | (1.1M) | 9.9M | 11.4M | 12.0M | |
| Net Invested Capital | (355.0K) | 224.1K | 10.3M | 7.3M | 3.7M | 3.5M | |
| Net Working Capital | (355.3K) | 224.1K | 10.3M | 6.9M | 3.5M | 3.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protagenic Therapeutics is a strong investment it is important to analyze Protagenic Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Protagenic Therapeutics' future performance. For an informed investment choice regarding Protagenic Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protagenic Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Protagenic Stock please use our How to Invest in Protagenic Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Protagenic Stock analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Protagenic Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. If investors know Protagenic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protagenic Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.37) | Return On Assets (0.67) | Return On Equity (1.41) |
The market value of Protagenic Therapeutics is measured differently than its book value, which is the value of Protagenic that is recorded on the company's balance sheet. Investors also form their own opinion of Protagenic Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protagenic Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protagenic Therapeutics' market value can be influenced by many factors that don't directly affect Protagenic Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protagenic Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protagenic Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.